Biomarkers of response to advanced prostate cancer therapy

Expert Rev Mol Diagn. 2020 Feb;20(2):195-205. doi: 10.1080/14737159.2020.1707669. Epub 2020 Jan 27.


Introduction: Prostate cancer (PCa) is one of the most common adult malignancies worldwide, and a major leading cause of cancer-related death in men in Western societies. In the last years, the prognosis of advanced PCa patients has been impressively improved thanks to the development of different therapeutic agents, including taxanes (docetaxel and cabazitaxel), second-generation anti-hormonal agents (abiraterone and enzalutamide), and the radiopharmaceutical Radium-223. However, great efforts are still needed to properly select the most appropriate treatment for each single patient.Areas covered: Several prognostic or predictive biomarkers have been studied, none of which has an established validated role in daily clinical practice. This paper analyzed the major biomarkers (including PSA, androgen receptor (AR) splice variants, βIII-tubulin, ALP, circulating tumor cells, and DNA repair genes) with a potential prognostic and/or predictive role in advanced PCa patients.Expert commentary: Surrogate biomarkers - measurable, reproducible, closely associated with tumor behavior and linked to relevant clinical outcomes - are urgently needed to improve PCa patient management.

Keywords: AR-V7; DRGs; PSA; Prostate cancer; biomarker.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor*
  • Clinical Decision-Making
  • Combined Modality Therapy
  • Disease Management
  • Drug Resistance, Neoplasm
  • Humans
  • Male
  • Neoplasm Staging
  • Neoplastic Cells, Circulating
  • Neoplastic Stem Cells
  • Precision Medicine / methods
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / etiology
  • Prostatic Neoplasms / therapy*
  • Treatment Outcome


  • Antineoplastic Agents
  • Biomarkers, Tumor